Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
necroptosis-based cancer therapy (Mosaic ImmunoEngineering)
- Development stage
- Preclinical
- Lead developer
- Mosaic ImmunoEngineering
- Modality
- Small Molecules
- Administration
- Intratumoral
01
Overview
This asset is a first-in-class small molecule necroptosis inducer being developed by Mosaic ImmunoEngineering under an exclusive option agreement with Oncotelic Therapeutics. The therapy is designed to activate the necroptosis pathway, a form of programmed, pro-inflammatory cell death that is distinct from apoptosis. By inducing necroptosis, the drug aims to release damage-associated molecular patterns (DAMPs) and tumor antigens into the microenvironment, thereby stimulating a robust systemic anti-tumor immune response. This approach is intended to convert immunologically "cold" tumors into "hot" tumors, potentially overcoming resistance to current immunotherapies such as checkpoint inhibitors. The program is currently in the preclinical stage of development for various oncology indications.
- Other names
- necroptosis inducernecroptosis-based cancer therapy
02
Targets
RIPK3MLKL (Mixed lineage kinase domain-like protein)
Beyond the preview
Go deeper on necroptosis-based cancer therapy (Mosaic ImmunoEngineering).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on necroptosis-based cancer therapy (Mosaic ImmunoEngineering).